XML 15 R6.htm IDEA: XBRL DOCUMENT v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2021
Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net loss $ (3,919) $ (7,732)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation expense 121 60
Amortization of intangible assets 307 15
Amortization of right-of-use assets and liabilities 25 152
Pro rata loss from equity method investment in Razor 270 329
Amortization of prepaid maintenance 21 36
Stock-based compensation 1,290 937
Unrealized (gain) loss on marketable equity securities (213) 53
Amortization of debt issuance costs 19 35
Change in fair value of contingent consideration 1,060
Deferred income tax benefit (7,564) (1,095)
Changes in operating assets and liabilities:    
Accounts receivable (499) 8
Amount due to Lineage and affiliates (6)
Prepaid expenses and other assets (1,168) (909)
Accounts payable and accrued liabilities 405 1,247
Net cash used in operating activities (9,845) (6,870)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Acquisition of Insight Genetics, net of cash acquired (607) (6,189)
Acquisition of Razor Genomics asset, net of cash acquired (6,648)
Deposit paid for Chronix merger agreement (175)
Construction in progress and purchases of furniture and equipment (842) (44)
Security deposit and other 10 42
Net cash used in investing activities (8,262) (6,191)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Proceeds from exercise of stock options 348
Proceeds from sale of common shares 65,262 7,597
Financing costs to issue common shares (2,676) (1)
Proceeds from sale of common shares under at-the-market transactions 6,754
Financing costs for at-the-market sales (203)
Proceeds from exercise of warrants 802
Common shares received and retired for employee taxes paid (14)
Repayment of loan payable (375)
Repayment of financing lease obligations (41) (17)
Net cash provided by financing activities 69,871 7,565
NET INCREASE (DECREASE) IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH 51,764 (5,496)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH:    
At beginning of the period 8,843 23,773
At end of the period 60,607 18,277
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION    
Cash paid for interest 44 43
SUPPLEMENTAL SCHEDULE OF NONCASH FINANCING AND INVESTING ACTIVITIES    
Common stock issued for acquisition of Razor Genomics asset 5,756
Deferred tax liability generated from the acquisition of Razor Genomics asset 7,564
Common stock issued for acquisition of Insight Genetics 5,000
Construction in progress, machinery and equipment purchases included in accounts payable, accrued liabilities and landlord liability 139
Initial fair value of contingent consideration at acquisition date 11,130
Holdback liability $ 600